These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6147186)

  • 1. [Determination of serum thyroid-stimulating immunoglobulin and its clinical significance in patients with Graves' disease].
    Leng S
    Zhonghua Yi Xue Za Zhi; 1984 Apr; 64(4):200-2. PubMed ID: 6147186
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of thyroid-binding immunoglobulins in patients with thyrotropin-mediated hyperthyroidism.
    Kourides IA; Pekonen F; Weintraub BD
    J Clin Endocrinol Metab; 1980 Aug; 51(2):272-4. PubMed ID: 6105164
    [No Abstract]   [Full Text] [Related]  

  • 3. Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.
    Wenzel KW; Lente JR
    J Endocrinol Invest; 1983 Oct; 6(5):389-94. PubMed ID: 6141202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating and eye muscle antibodies in Graves' disease and Graves' orbitopathy.
    Kahaly G; Grübl M; Moncayo R; Schilling S; Weber P; Beyer J; Krause U
    Dev Ophthalmol; 1989; 20():68-78. PubMed ID: 2574117
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
    Bech K
    Acta Endocrinol Suppl (Copenh); 1983; 254():3-38. PubMed ID: 6191508
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thyroid-stimulating immunoglobulins in Graves disease. Usefulness of a radioreceptor assay].
    Gómez Sáez JM; Navarro Moreno MA; Montaña Mias E; Macià Montserrat M
    Med Clin (Barc); 1986 Oct; 87(10):410-2. PubMed ID: 2878127
    [No Abstract]   [Full Text] [Related]  

  • 7. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid stimulating immunoglobulin in Graves' disease.
    Luttrell BM; Hales IB
    Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 12. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
    Bednarek J; Wysocki H; Sowiński J
    Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow up of Graves' patients thyroid stimulating antibody activity during treatment. A prospective study.
    Bakó G; Lenkey A; Szabó T; Karanyi Z; Forizs E; Kálmán K; Szabó J; Varvölgyi C; Leövey A
    Radiobiol Radiother (Berl); 1987; 28(5):600-4. PubMed ID: 2894709
    [No Abstract]   [Full Text] [Related]  

  • 14. A new method for assessing the thyrotropin binding inhibitory activity in the immunoglobulins and whole serum of patients with Graves' disease.
    Borges M; Ingbar JC; Endo K; Amir S; Uchimura H; Nagataki S; Ingbar SH
    J Clin Endocrinol Metab; 1982 Mar; 54(3):552-8. PubMed ID: 6120179
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between thyroid adenylate cyclase-stimulating and thyrotropin-binding inhibitor immunoglobulins in Graves' disease.
    Chang TC; Chen FW; Chang CC; Liaw KY
    Taiwan Yi Xue Hui Za Zhi; 1985 May; 84(5):579-85. PubMed ID: 2864384
    [No Abstract]   [Full Text] [Related]  

  • 16. Determination of thyroid-binding inhibiting immunoglobulins using unextracted serum.
    Yap SF; Ngan A; Zaini A
    Malays J Pathol; 1987 Aug; 9():67-71. PubMed ID: 2898571
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical evaluation of biotin-binding immunoglobulin in patients with Graves' disease.
    Nagamine T; Takehara K; Fukui T; Mori M
    Clin Chim Acta; 1994 Apr; 226(1):47-54. PubMed ID: 7915219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of serum angiotensin-converting enzyme activity during treatment of patients with Graves' disease.
    Lee DS; Chung JK; Cho BY; Koh CS; Lee M
    Korean J Intern Med; 1986 Jan; 1(1):104-12. PubMed ID: 15759385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thyroid-stimulating antibodies in Graves' ophthalmopathy].
    Gómez Sáez JM; Soler Ramón J; Navarro Moreno MA
    Med Clin (Barc); 1983 Nov; 81(17):755-7. PubMed ID: 6140337
    [No Abstract]   [Full Text] [Related]  

  • 20. Pregnancy and PTU.
    Solomon DH
    N Engl J Med; 1981 Feb; 304(9):538-9. PubMed ID: 6109251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.